A COMPARATIVE STUDY OF SAFETY AND EFFICACY OF BETAMETHASONE ORAL MINI PULSE (BOMP) AND WEEKLY AZATHIOPRINE PULSE (WAP) IN THE TREATMENT OF ALOPECIA AREATA
Durgesh Sonare*, Rekha Seervi, Gauri Vats, Manish Meena, Rohit Kataria and Vinod Jain
ABSTRACT
Alopecia areata is an autoimmune disease, characterized by non-scarring hair loss on the scalp or any hair bearing surface.[1] Alopecia areata is common disease.[2] The lifetime risk of developing this condition is reported to be 1.7%.[3] Men and women are equally affected with same prevalence in all ethnic groups.[4,5] AA can occur at any age, but the peak incidence appears to be between 15 and 29 years of age.[6] Pediatric AA constitutes approximately 20% of AA cases.[7] A very few studies are conducted in this area focusing specially on children with alopecia areata.[8,9] AA is reported to occur before the age of 16 years in 11% to 23.9% of the affected population. Traditionally it has been classified as an acquired disorder.[10] However, it is rarely reported in infancy.[11,12] and even less so in the neonatal period.[13,14]
[Full Text Article] [Download Certificate]